Dermatology Times

Dermatology Times is a weekly publication that serves as a key resource for dermatologists. It provides trustworthy, pertinent, and up-to-date coverage of the newest developments in the field of dermatology.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#251550

United States

#100692

Health/Medicine

#887

Traffic sources

Monthly visitors

Articles

Journal Digest: April 16

1 week ago | dermatologytimes.com | Emma Andrus

JEADV Clinical Practice: Exploring the Cutaneous Associations of Crohn's Disease: A Retrospective Study of 108 PatientsA recent retrospective chart review examined dermatologic associations in patients with Crohn disease seen at Wake Forest Baptist Dermatology between 2010 and 2024. Researchers analyzed 108 patient records, with statistical comparisons made using χ² and 2-tailed t-tests. The majority of patients were female (54.6%) and White (80.6%).
Daily Derm Times: April 15, 2025

1 week ago | dermatologytimes.com | Emma Andrus

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Facial hyperpigmentation may signal systemic disease. Dermatologists must assess beyond melasma to ensure timely, accurate diagnosis and care. In a large study, nearly half of SIND patients also had other BFRBs like skin picking or hair pulling. Evommune has initiated a global phase 2b trial of EVO756, a first-in-class MRGPRX2 antagonist, for moderate to severe CSU.
Evommune Advances EVO756 Into Global Phase 2b Trial for Chronic Spontaneous Urticaria

1 week ago | dermatologytimes.com | Emma Andrus

Evommune, Inc.
Daily Derm Times: April 14, 2025

1 week ago | dermatologytimes.com | Emma Andrus

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Experts explore how rosacea research is evolving, with new treatments, gaps in care, and a push for more inclusive, targeted approaches. Untreated or undertreated AD can lead to poor sleep, infections, and stunted development. The novel formulation was compared to a petrolatum-based diaper and was found to be just as effective for irritation and redness.
Women with Psoriasis More Likely to Discontinue Biologics Than Men, Study Finds

1 week ago | dermatologytimes.com | Pearl Steinzor

Women with psoriasis may be more likely than men to discontinue biologic treatments, including newer options like IL-17 and IL-23 inhibitors, due to differences in treatment satisfaction and adverse events (AEs), according to one study.1The prospective, multicenter study is published in the Journal of Psoriasis and Psoriatic Arthritis.
HyBryte Achieves 75% Treatment Success by Week 18 in Ongoing CTCL Trial

1 week ago | dermatologytimes.com | Emma Andrus

New interim data from an ongoing investigator-initiated study demonstrates the potential of Soligenix, Inc.'s HyBryte (synthetic hypericin), formerly SGX301, as a promising treatment option for early-stage cutaneous T-cell lymphoma (CTCL).1Soligenix released these latest findings, which showed strong early efficacy and safety results, that reaffirm prior phase 3 trial outcomes.
Dermatology Times' Sunday Crossword: April 13, 2025

1 week ago | dermatologytimes.com | Emma Andrus

Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.
Daily Derm Times: April 11, 2025

1 week ago | dermatologytimes.com | Emma Andrus

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Menopausal acne is rising yet underexplored; treatment must address hormonal shifts, skin sensitivity, and patient emotional well-being. The company also announced in a press release that the product received the Seal of Acceptance by the NEA. Subcutaneous methotrexate may offer improved efficacy and patient adherence in psoriasis treatment, though it comes at a higher cost.
Subcutaneous Methotrexate Shows Promise Over Oral Route in Plaque Psoriasis Treatment

1 week ago | dermatologytimes.com | Emma Andrus

A recent literature review examined the effectiveness of subcutaneous methotrexate in patients with plaque psoriasis.1The review, published in the International Journal of Dermatology, reported greater efficacy in cases of subcutaneous administration versus oral therapy. While methotrexate has long been used in psoriatic disease due to its efficacy and cost-effectiveness,2 the choice between oral and subcutaneous administration routes has remained an area of ongoing clinical discussion.
Daily Derm Times: April 10, 2025

2 weeks ago | dermatologytimes.com | Emma Andrus

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Bill Damsky, MD, PhD, pioneers molecular diagnostics to close the gap between research and clinical care in inflammatory skin disease. A new subgroup analysis revealed higher rates of clear or almost clear skin at week 16 vs placebo with a favorable safety profile.